Summit Therapeutics PLC  

(Public, LON:SUMM)   Watch this stock  
Find more results for SUMM
182.50
0.00 (0.00%)
Feb 27 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range     -
52 week 100.00 - 239.50
Open     -
Vol / Avg. 0.00/91,371.00
Mkt cap 75.04M*
P/E     -
Div/yield     -
EPS     -
Shares 41.12M
Beta     -
Inst. own     -
*GBP
Feb 19, 2015
Summit Corporation PLC Annual Shareholders Meeting
  

Key stats and ratios

Q4 (Oct '14) 2014
Net profit margin - -443.13%
Operating margin - -487.93%
EBITD margin - -487.05%
Return on average assets -43.89% -104.40%
Return on average equity -52.12% -160.07%
Employees 17 -
CDP Score - -

Address

85B Park Drive
ABINGDON, OX14 4RY
United Kingdom - Map
+44-1235-443939 (Phone)
+44-1235-436237 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Summit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based drug discovery and development company. The Company is engaged in developing drug candidates to treat Duchenne Muscular Dystrophy (DMD), a genetic disease, and Clostridium difficile Infection (CDI), an infectious disease. The Company is developing a pipeline of utrophin modulators that comprise its lead candidate SMT C1100 and next generation modulators that are at an earlier stage of development. SMT C1100 is in a Phase 1b clinical trial. The Company is developing SMT19969 as an antibiotic that is a potential treatment for initial CDI that could significantly reduce rates of recurrent disease. SMT19969 completed a Phase 1 clinical trial in healthy volunteers with the results showing it to be safe and well tolerated at all doses tested, including the expected therapeutic dose. The Company�s subsidiaries include Summit (Oxford) Limited and Summit (Wales) Limited.

Officers and directors

Glyn Edwards Chief Executive Officer, Executive Director
Age: 58
Erik Ostrowski Chief Financial Officer
Age: 41
Frank Murdoch Armstrong Non-Executive Chairman of the Board
Age: 56
Valerie L. Andrews Non-Executive Director
Age: 55
Stephen J. Davies Non-Executive Director
Age: 64
Barry J. Price Ph.D. Non-Executive Director
Age: 70
David M. Wurzer CPA Non-Executive Director
Age: 56